Literature DB >> 20952513

Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.

Bo Zhang1, Xiao-Xiao Liu, Jian-Rong He, Ci-Xiang Zhou, Meng Guo, Ming He, Mei-Fang Li, Guo-Qiang Chen, Qian Zhao.   

Abstract

The role of miR-26a in carcinogenesis appears to be a complicated one, in the sense that both oncogenic and tumor suppressive effects were reported in cancers such as glioblastoma and hepatocellular carcinoma, respectively. Here, we report for the first time that miR-26a is downregulated in breast cancer specimens and cell lines and its transient transfection initiates apoptosis of breast cancer cell line MCF7 cells. Furthermore, retrovirus-delivered miR-26a impairs the in vitro colony forming and in vivo tumor-loading ability of MCF7 cells. Subsequently, MTDH and EZH2 are identified as two direct targets of miR-26a and they are significantly upregulated in breast cancer. MCF7 xenografts with exogenous miR-26a show that a decrease in expression of both MTDH and EZH2 is accompanied by an increase in apoptosis. Moreover, knockdown of MTDH causes apoptosis while reexpression of MTDH partially reverses the proapoptotic effect of miR-26a in MCF7 cells. Our findings suggest that miR-26a functionally antagonizes human breast carcinogenesis by targeting MTDH and EZH2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952513     DOI: 10.1093/carcin/bgq209

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  98 in total

1.  Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice.

Authors:  Jyoti Srivastava; Ayesha Siddiq; Rachel Gredler; Xue-Ning Shen; Devaraja Rajasekaran; Chadia L Robertson; Mark A Subler; Jolene J Windle; Catherine I Dumur; Nitai D Mukhopadhyay; Dawn Garcia; Zhao Lai; Yidong Chen; Uthra Balaji; Paul B Fisher; Devanand Sarkar
Journal:  Hepatology       Date:  2015-01-23       Impact factor: 17.425

2.  Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer.

Authors:  Mayuko Kato; Akira Kurozumi; Yusuke Goto; Ryosuke Matsushita; Atsushi Okato; Rika Nishikawa; Ichiro Fukumoto; Keiichi Koshizuka; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

3.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

4.  Perturbation of epigenetic processes by doxorubicin in the mouse testis.

Authors:  Oluwajoba O Akinjo; Timothy W Gant; Emma L Marczylo
Journal:  Toxicol Res (Camb)       Date:  2016-06-01       Impact factor: 3.524

5.  An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth.

Authors:  Toshihiko Tanno; Peng Zhang; Christopher A Lazarski; Yang Liu; Pan Zheng
Journal:  Blood Adv       Date:  2017-06-22

6.  MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19.

Authors:  Yanping Gong; Wenshuang Wu; Xiuhe Zou; Feng Liu; Tao Wei; Jingqiang Zhu
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

7.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

8.  The role of miR-26 in tumors and normal tissues (Review).

Authors:  Jie Gao; Qing-Guang Liu
Journal:  Oncol Lett       Date:  2011-09-05       Impact factor: 2.967

9.  Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.

Authors:  Yong Yang; Peng Zhang; Yanfeng Zhao; Jie Yang; Gening Jiang; Jie Fan
Journal:  Cancer Biol Ther       Date:  2015-10-22       Impact factor: 4.742

10.  Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1.

Authors:  Kai Guo; Shaobo Zheng; Yawen Xu; Abai Xu; Binshen Chen; Yong Wen
Journal:  Tumour Biol       Date:  2016-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.